Jeffrey Allen Bailey's most recent trade in Aurinia Pharmaceuticals Inc was a trade of 2,716 Common Shares done at an average price of $15.7 . Disclosure was reported to the exchange on Nov. 21, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aurinia Pharma Inc | Jeffrey Allen Bailey | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.68 per share. | 21 Nov 2025 | 2,716 | 22,775 (0%) | 0% | 15.7 | 42,587 | Common Shares |
| Aurinia Pharma Inc | Jeffrey Allen Bailey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2025 | 37,485 | 37,485 | - | - | Director Stock Option (right to buy) | |
| Aurinia Pharma Inc | Jeffrey Allen Bailey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 18,641 | 18,641 | - | - | Director Stock Option (right to buy) | |
| Aurinia Pharma Inc | Jeffrey Allen Bailey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 12,135 | 25,491 (0%) | 0% | 0 | Common Shares | |
| Aurinia Pharma Inc | Jeffrey Allen Bailey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2024 | 17,913 | 0 | - | - | Restricted Stock Units | |
| Aurinia Pharma Inc | Jeffrey Allen Bailey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2024 | 17,913 | 17,913 (0%) | 0% | - | Common Stock | |
| Aurinia Pharma Inc | Jeffrey Allen Bailey | Director | Sale of securities on an exchange or to another person at price $ 8.43 per share. | 08 Nov 2024 | 4,557 | 13,356 (0%) | 0% | 8.4 | 38,416 | Common Stock |
| Aurinia Pharma Inc | Jeffrey Allen Bailey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2023 | 28,959 | 28,959 | - | - | Stock Option (right to buy) | |
| Aurinia Pharma Inc | Jeffrey Allen Bailey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2023 | 17,913 | 17,913 | - | - | Restricted Stock Units | |
| Rein Therapeutics Inc | Jeffrey Allen Bailey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 96,000 | 96,000 | - | - | Stock Option (right to buy) |